Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Conmed (CNMD) Change in Receivables (2016 - 2025)

Conmed's Change in Receivables history spans 16 years, with the latest figure at $22.7 million for Q4 2025.

  • For Q4 2025, Change in Receivables rose 82.83% year-over-year to $22.7 million; the TTM value through Dec 2025 reached $2.4 million, up 45.83%, while the annual FY2025 figure was $2.4 million, 45.83% up from the prior year.
  • Change in Receivables reached $22.7 million in Q4 2025 per CNMD's latest filing, up from -$9.2 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $22.7 million in Q4 2025 to a low of -$19.0 million in Q1 2025.
  • Average Change in Receivables over 5 years is $3.3 million, with a median of $1.9 million recorded in 2023.
  • Peak YoY movement for Change in Receivables: skyrocketed 12578.53% in 2023, then tumbled 2190.75% in 2025.
  • A 5-year view of Change in Receivables shows it stood at $19.0 million in 2021, then crashed by 157.16% to -$10.9 million in 2022, then soared by 183.14% to $9.1 million in 2023, then surged by 36.97% to $12.4 million in 2024, then soared by 82.83% to $22.7 million in 2025.
  • Per Business Quant, the three most recent readings for CNMD's Change in Receivables are $22.7 million (Q4 2025), -$9.2 million (Q3 2025), and $7.8 million (Q2 2025).